FindTrial
Sign In

A Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations

A Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN43344383
Enrollment
Unknown
Registered
2002-08-19
Start date
1990-01-01
Completion date
Unknown
Last updated
2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukaemia (acute), Leukaemia (chronic) Cancer Leukaemia (acute), Leukaemia (chronic)

Interventions

1. Arm A: Patients receive standard non-filtered, non-leukocyte-depleted blood products 2. Arm B: Patients receive Pall filtered blood or platelet donations

Sponsors

Pall Biomedical Ltd (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with acute leukaemia, chronic myeloid leukaemia, severe aplastic anaemia or high grade lymphoma 2. Patients already known to have Human Leukocyte Antigens (HLA) antibodies or recurrent febrile transfusion reactions are ineligible 3. Any age 4. Fit to undergo the treatments as defined in protocol

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026